International Journal of Radiation Oncology * Biology * Physics
Volume 78, Issue 1 , Pages 50-57 , 1 September 2010

Hypofractionated Boost to the Dominant Tumor Region With Intensity Modulated Stereotactic Radiotherapy for Prostate Cancer: A Sequential Dose Escalation Pilot Study

  • Raymond Miralbell, M.D.

      Affiliations

    • Servei de Radio-oncologia, Institut Oncòlogic Teknon, Barcelona, Spain
    • Service de Radio-oncologie, Hôpitaux Universitaires de Genève, Geneva, Switzerland
    • Corresponding Author InformationReprint requests to: Raymond Miralbell, M.D., Radiation Oncology Department, University Hospital of Geneva, 1211 Geneva 14, Switzerland. Tel: +4122-3827102; Fax: +4122-3827117
    • ,
  • Meritxell Mollà, M.D.

      Affiliations

    • Servei de Radio-oncologia, Institut Oncòlogic Teknon, Barcelona, Spain
    • ,
  • Michel Rouzaud, D.Sc.

      Affiliations

    • Service de Radio-oncologie, Hôpitaux Universitaires de Genève, Geneva, Switzerland
    • ,
  • Alberto Hidalgo, M.D.

      Affiliations

    • Servei de Radiodiagnòstic, Centro Médico Teknon, Barcelona, Spain
    • ,
  • José Ignacio Toscas, M.D.

      Affiliations

    • Servei de Radio-oncologia, Institut Oncòlogic Teknon, Barcelona, Spain
    • ,
  • Joan Lozano, M.D.

      Affiliations

    • Servei de Radio-oncologia, Institut Oncòlogic Teknon, Barcelona, Spain
    • ,
  • Sergi Sanz, B.Sc.

      Affiliations

    • Statistics Department, Barcelona Centre for International Health Research (CRESIB), Barcelona, Spain
    • ,
  • Carmen Ares, M.D.

      Affiliations

    • Service de Radio-oncologie, Hôpitaux Universitaires de Genève, Geneva, Switzerland
    • ,
  • Sandra Jorcano, M.D.

      Affiliations

    • Servei de Radio-oncologia, Institut Oncòlogic Teknon, Barcelona, Spain
    • ,
  • Dolors Linero, D.Sc.

      Affiliations

    • Servei de Radio-oncologia, Institut Oncòlogic Teknon, Barcelona, Spain
    • ,
  • Lluís Escudé, D.Sc.

      Affiliations

    • Servei de Radio-oncologia, Institut Oncòlogic Teknon, Barcelona, Spain

Received 2 February 2009 ,Revised 18 June 2009 ,Accepted 18 July 2009.

References 

  1. Hanks GE, Martz KL, Diamond JJ. The effect of dose on local control of prostate cancer. Int J Radiat Oncol Biol Phys. 1988;15:1299–1306
  2. Zelefsky MJ, Leibel SA, Gaudin PB, et al. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys. 1998;41:491–500
  3. Vicini FA, Abner A, Baglan KL, et al. Defining a dose-response relationship with radiotherapy for prostate cancer: Is more really better?. Int J Radiat Oncol Biol Phys. 2001;51:1200–1208
  4. Fiveash JB, Hanks G, Roach M, et al. 3D conformal radiation therapy (3DCRT) for high grade prostate cancer: A multi-institutional review. Int J Radiat Oncol Biol Phys. 2000;47:335–342
  5. Hanks GE, Hanlon AL, Epstein B, Horwitz EM. Dose response in prostate cancer with 8–12 years' follow-up. Int J Radiat Oncol Biol Phys. 2002;54:427–435
  6. Kupelian P, Kuban D, Thames H, et al. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: The combined experience of nine institutions in patients treated in 1994 and 1995. Int J Radiat Oncol Biol Phys. 2005;61:415–419
  7. Sathya JR, Davis IR, Julian JA, et al. Randomized trial comparing Iridium implants plus external-beam radiation therapy with external-beam radiation therapy alone in node-negative locally advanced cancer of the prostate. J Clin Oncol. 2005;23:1192–1199
  8. Pollack A, Zagars GK, Starkschall G, et al. Prostate cancer radiation dose response: Results of the M.D. Anderson Phase III randomized trial. Int J Radiat Oncol Biol Phys. 2002;53:1097–1105
  9. Zietman AL, DeSilvio ML, Slater JD, et al. Comparison of conventional-dose vs. high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate. A randomized controlled trial. J Am Med Assoc. 2005;294:1233–1239
  10. Zelefsky ML, Fuks Z, Hunt M, et al. High-dose intensity modulated radiation therapy for prostate cancer: Early toxicity and biochemical outcome in 772 patients. Int J Radiat Oncol Biol Phys. 2002;53:1111–1116
  11. Kupelian PA, Willoughby TR, Reddy CH, et al. Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland clinic experience. J Clin Oncol. 2007;68:1424–1430
  12. Åstrom L, Pedersen D, Mercke C, et al. Long-term outcome of high-dose rate brachytherapy in radiotherapy of localised prostate cancer. Radiother Oncol. 2005;74:151–157
  13. Demanes DJ, Rodriguez RR, Schour L, et al. High-dose rate intensity-modulated brachytherapy with external beam radiotherapy for prostate cancer: California endocurietherapy's 10-year results. Int J Radiat Oncol Biol Phys. 2005;61:1306–1316
  14. Duchesne GM, Williams SG, Das R, Tai KH. Patterns of toxicity following high-dose rate brachytherapy boost for prostate cancer: Mature prospective phase I/II study results. Radiother Oncol. 2007;84:128–134
  15. Galalae RM, Kovács G, Schultze J, et al. Long-term outcome after elective irradiation of the pelvic lymphatics and local dose escalation using high-dose-rate brachytherapy for locally advanced prostate cancer. Int J Radiat Oncol Biol Phys. 2002;52:81–90
  16. Hoskin PJ, Motohashi K, Bownes P, et al. High dose rate brachytherapy in combination with external beam radiotherapy in the radical treatment of prostate cancer: Initial results of a randomised phase three trial. Radiother Oncol. 2007;84:114–120
  17. Martin T, Roddiger S, Kurek R, et al. 3D conformal HDR brachytherapy and external beam irradiation combined with temporary androgen deprivation in the treatment of localized prostate cancer. Radiother Oncol. 2004;71:35–41
  18. Brenner DJ, Martinez AA, Edmundson GK, et al. Direct evidence that prostate tumors show high sensitivity to fractionation (low alfa/beta ratio) similar to late-responding normal tissue. Int J Radiat Oncol Biol Phys. 2002;52:6–13
  19. Brenner DJ. Hypofractionation for prostate cancer radiotherapy—what are the issues. Int J Radiat Oncol Biol Phys. 2003;57:912–914
  20. Logue JP, Hendry JH. Hypofractionation for prostate cancer. Int J Radiat Oncol Biol Phys. 2001;49:152
  21. Cheng ME, Johnston DA, Tang K, et al. Detailed mapping of prostate carcinoma foci: Biopsy strategy implications. Cancer. 2000;89:1800–1809
  22. Parker C, Warde P, Catton C. Salvage radiotherapy for PSA failure after radical prostatectomy. Radiother Oncol. 2001;61:107–116
  23. Ares C, Popowski Y, Pampallona S, et al. Hypofractionated boost with high-dose rate brachytherapy and open MRI-guided implants for locally aggressive prostate cancer: A sequential dose escalation pilot study. Int J Radiat Oncol Biol Phys. 2009 Feb 26;[Epub ahead of print]
  24. Roach M, Marquez C, Yuo H-S, et al. Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 1993;28:33–37
  25. Bieri S, Miralbell R, Nouet P, et al. Reproducibility of conformal radiation therapy in localized carcinoma of the prostate without rigid immobilization. Radiother Oncol. 1996;38:223–230
  26. Soete G, Verellen D, Michielsen D, et al. Clinical use of stereoscopic X-ray positioning of patients treated with conformal radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2002;54:948–952
  27. Miralbell R, Mollà M, Arnalte R, et al. Target repositioning optimization in prostate cancer: Is intensity modulation radiotherapy under stereotactic conditions feasible?. Int J Radiat Oncol Biol Phys. 2004;59:366–371
  28. D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. J Am Med Assoc. 1998;280:969–974
  29. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995;31:1341–1346
  30. Roach M, Hanks G, Thames H, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006;65:965–974
  31. Kaplan EL, Meier P. Nonparametric Estimation from Incomplete Observations. J Am Stat Assoc. 1958;53:457–481
  32. Kuban D, Pollack A, Huang E, et al. Hazards of dose escalation in prostate cancer radiotherapy. Int J Radiat Oncol Biol Phys. 2003;57:1260–1268
  33. Dearnaley DP, Hall E, Lawrence D, et al. Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. British Journal of Cancer. 2005;92:488–498
  34. Kauczor H-U, Zechmann C, Stieltjes B, Weber M-A. Functional magnetic resonance imaging for definig the biological target volume. Cancer Imaging. 2006;6:51–55
  35. Hara T, Kosaka N, Kishi H. PET imaging of prostate cancer using carbon-11 choline. J Nucl Med. 1998;39:990–995
  36. Oyama N, Akino H, Kanamaru H, et al. 11C Acetate PET Imaging of Prostate Cancer. J Nucl Med. 2002;43:181–186
  37. Price DT, Coleman E, Liao RP, et al. Comparison of 18F Fluorocholine and 18F Fluorodeoxyglucose for positron emission tomography of androgen dependents and androgen independent prostate cancer. J Urol. 2002;168:273–280
  38. Lee NY, Mechalakos JG, Nehmeh S, et al. Fluorine-18-labeled fluoromisonidazole positron emission and computed tomography-guided intensity-modulated radiotherapy for head and neck cancer: A feasibility study. Int J Radiat Oncol Biol Phys. 2008;70:2–13

 Conflict of interest: none.

PII: S0360-3016(09)02767-9

doi: 10.1016/j.ijrobp.2009.07.1689

International Journal of Radiation Oncology * Biology * Physics
Volume 78, Issue 1 , Pages 50-57 , 1 September 2010

Article Tools

* Image Usage & Resolution